The estimated Net Worth of John L Higgins is at least $37.4 Million dollars as of 8 July 2024. Mr. Higgins owns over 6,000 units of Ligand Pharmaceuticals stock worth over $4,392,459 and over the last 21 years he sold LGND stock worth over $26,231,644. In addition, he makes $6,770,380 as Chief Executive Officer und Director at Ligand Pharmaceuticals.
John has made over 54 trades of the Ligand Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of LGND stock worth $137,700 on 8 July 2024.
The largest trade he's ever made was exercising 120,000 units of Ligand Pharmaceuticals stock on 25 January 2021 worth over $1,959,600. On average, John trades about 6,204 units every 50 days since 2004. As of 8 July 2024 he still owns at least 42,608 units of Ligand Pharmaceuticals stock.
You can see the complete history of Mr. Higgins stock trades at the bottom of the page.
John L. Higgins serves as Chief Executive Officer, Director of the Company. Prior to joining our company, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations & governance committee of Bio-Techne Corporation, a publicly-traded life sciences services. Mr. Higgins has served as a director on numerous public and private companies. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Mr. Higgins’ executive experience operating and managing public biotechnology companies, his prior service on other company boards and his financial transaction experience as an investment banker in the biopharmaceutical industry contributed to our board of directors’ conclusion that he should serve as a director of our company.
As the Chief Executive Officer und Director of Ligand Pharmaceuticals, the total compensation of John Higgins at Ligand Pharmaceuticals is $6,770,380. There are no executives at Ligand Pharmaceuticals getting paid more.
John Higgins is 50, he's been the Chief Executive Officer und Director of Ligand Pharmaceuticals since 2015. There are 11 older and 6 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.
John's mailing address filed with the SEC is 614, Northeast McKinley Place, Minneapolis, Hennepin County, Minnesota, 55413, United States.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: